Richard F. Riedel, MD

Richard F. Riedel, MD, discusses the importance of multidisciplinary PEComa management and the role of sarcoma specialists in this disease setting.

Panelists discuss how communication between community oncologists and academic centers is essential for advancing gastrointestinal stromal tumor (GIST) treatment through clinical trial participation, molecular analysis, and the promising future of personalized therapy based on individual tumor mutation profiles.

Panelists discuss how newer clinical trials such as PEAK and INSIGHT are investigating combination therapies and mutation-specific treatment approaches to overcome secondary resistance mutations, while also exploring pan-KIT inhibitors and senescence-targeting strategies to improve outcomes.

Panelists discuss how most gastrointestinal stromal tumor (GIST) patients can tolerate approved agents with proper adverse effect management, the efficacy data from the INVICTUS and INTRIGUE trials that led to ripretinib's approval, and the unique adverse effects such as alopecia that distinguish ripretinib from other therapies.

Panelists discuss how patient adherence to kinase inhibitors is crucial for disease control, requiring proactive adverse effect management, careful radiological monitoring, and strategies such as dose escalation to maximize treatment duration and effectiveness.

Panelists discuss how standard-of-care treatment follows NCCN guidelines with sequential kinase inhibitor therapy (imatinib, sunitinib, regorafenib, ripretinib), emphasizing that maintaining some form of kinase inhibition is always preferable to no treatment even after progression.

Panelists discuss how mutational testing is critical for gastrointestinal stromal tumor (GIST) management, with different genetic alterations determining treatment sensitivity and the importance of understanding both primary drivers and secondary resistance mutations that develop over time.

Panelists discuss how gastrointestinal stromal tumors (GISTs) are the most common sarcoma with specific genetic mutations, requiring comprehensive mutational analysis to guide treatment decisions and understand both primary and secondary resistance patterns.

Richard F. Riedel, MD, discusses the challenges of diagnosing and treating patients with desmoid tumors.

Richard F. Riedel, MD, associate professor of medicine, Duke Cancer Institute, discusses targeted therapy options for patients with uterine sarcomas.

Richard F. Riedel, MD, associate professor of medicine, Duke Cancer Institute, discusses the emerging role of immunotherapy in uterine sarcoma.

Richard F. Riedel, MD, associate professor of medicine, Duke Cancer Institute, discusses the rarity and characteristics of uterine sarcomas.

Richard F. Riedel, MD, associate professor of medicine, Duke Cancer Institute, discusses the treatment landscape of uterine sarcomas.